City Clinical Hospital #2

Pyatigorsk 357538

0 studies enrolling now · 2 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed